If you learn only one piece of glioma biology, make it this one: IDH status. It is arguably the single most important molecular fact about an adult diffuse glioma.
IDH stands for isocitrate dehydrogenase, an enzyme involved in cell metabolism. In some gliomas, the gene for this enzyme is mutated; in others it is normal, or "wildtype." That one difference splits gliomas into two groups that behave quite differently.
- IDH-mutant gliomas tend to occur in younger adults, often grow more slowly, and generally carry a more favorable outlook. Astrocytomas and oligodendrogliomas in this category are usually diagnosed at a younger age and can sometimes be managed over many years.
- IDH-wildtype gliomas in adults are more likely to be aggressive. In fact, under current rules, an aggressive IDH-wildtype diffuse astrocytic tumor in an adult is generally classified as glioblastoma.
This single marker now does several jobs at once. It helps name the tumor, helps grade it, helps predict how it is likely to behave, and — as of recently — helps treat it. In 2024, the FDA approved vorasidenib (Voranigo), the first targeted therapy aimed specifically at IDH-mutant grade 2 gliomas, for adults and children 12 and older after surgery. It works by blocking the mutant IDH enzyme and, in a large trial, significantly delayed tumor growth.
A note on balance: IDH-mutant generally carries a better prognosis than IDH-wildtype, but better is not the same as benign. IDH-mutant gliomas are still serious tumors that need expert care and long-term monitoring, and they can change into higher grades over time. Still, knowing your IDH status is one of the most empowering facts you can have, because it shapes nearly every decision ahead.